Imipramine
Janimine, Pramine, Presamine, Tofranil, Tofranil-pm (imipramine) is a small molecule pharmaceutical. Imipramine was first approved as Janimine on 1982-01-01. It is used to treat attention deficit disorder with hyperactivity, depressive disorder, enuresis, pain, and panic disorder amongst others in the USA. The pharmaceutical is active against sodium-dependent noradrenaline transporter and sodium-dependent serotonin transporter. In addition, it is known to target muscarinic acetylcholine receptor M2, potassium voltage-gated channel subfamily H member 1, G protein-activated inward rectifier potassium channel 2, and G protein-activated inward rectifier potassium channel 4.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Imipramine hydrochloride
Imipramine pamoate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TOFRANIL-PM | SPECGX | N-017090 DISCN | 1982-01-01 | 4 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| imipramine hydrochloride | ANDA | 2023-06-01 |
| tofranil | ANDA | 2016-12-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
| depressive disorder | EFO_1002014 | D003866 | F32.A |
| enuresis | — | D004775 | R32 |
| pain | EFO_0003843 | D010146 | R52 |
| panic disorder | EFO_0004262 | D016584 | F41.0 |
| psychotic affective disorders | — | D000341 | F39 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | IMIPRAMINE |
| INN | imipramine |
| Description | Imipramine is a dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom. It has a role as an adrenergic uptake inhibitor, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor and an antidepressant. It derives from a hydride of a 5H-dibenzo[b,f]azepine. |
| Classification | Small molecule |
| Drug class | antidepressants (imipramine type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCCN1c2ccccc2CCc2ccccc21 |
Target
Agency Approved
SLC6A2
SLC6A2
SLC6A4
SLC6A4
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Alternate
CHRM2
CHRM2
KCNH1
KCNH1
KCNJ6
KCNJ6
KCNJ5
KCNJ5
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,860 documents
View more details
Safety
Black-box Warning
Black-box warning for: Imipramine hydrochloride, Tofranil
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
36 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more